查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1969266

水痘天疱疮市场：按药物类别、给药途径、治疗线和最终用户划分 - 全球预测 2026-2032

Bullous pemphigoid Market by Drug Class, Route Of Administration, Therapy Line, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，水痘天疱疮市场价值将达到 3.7975 亿美元，到 2026 年将成长至 4.0244 亿美元，到 2032 年将达到 5.7414 亿美元，年复合成长率为 6.08%。

主要市场统计数据
基准年 2025 3.7975亿美元
预计年份：2026年 4.0244亿美元
预测年份 2032 5.7414亿美元
复合年增长率 (%) 6.08%

水痘天疱疮的简明临床和策略概述：病理生理学、未满足的医疗需求、不断发展的治疗方法以及相关人员的优先事项。

水痘天疱疮是一种常见的自体免疫水痘疾病，主要影响老年人，其特征是由针对半桥粒蛋白的自身抗体引起的表皮下水痘形成。临床症状差异很大，从局部搔痒性皮疹到广泛性张力性水痘，并伴随继发性感染的风险，严重影响患者的功能状态和生活品质。诊断通常包括临床评估（含直接萤光检查）、BP180和BP230自体抗体检测以及组织病理学检查，以与其他水痘疾病鑑别。

水痘天疱疮的诊断、临床实践模式和治疗创新正在发生变革性变化：跨越医疗保健机构和学科。

近年来，水痘天疱疮的诊断路径、治疗策略制定和诊疗模式都发生了变革性变化。免疫诊断技术的进步以及临床医生对自身抗体谱的深入理解，降低了诊断的不确定性。同时，更新的指引也越来越强调长期治疗中减少荷尔蒙用量的重要性。此外，生物目标製剂的临床证据和真实世界经验促使人们重新评估其获益风险，并为长期高剂量糖皮质激素治疗提供了替代方案。

美国计划于 2025 年实施的关税调整预计将对供应链、采购、价格压力和跨境物流产生累积影响。

美国提案的2025年关税调整可能会影响药品供应链、采购惯例和价格谈判。进口药品原料药、生物製药成分或成品的关税增加，可能会推高製造商和合约製造商的投入成本，促使他们重新评估供应商组合。为此，各企业可能会考虑将生产转移到近岸地区、实现原料药来源多元化，并签订长期供应合同，以稳定投入成本并降低海关延误带来的风险。

依治疗领域分類的策略资讯：治疗分类、给药途径、通路、终端用户趋势、对治疗线的影响。

水痘天疱疮的细分市场趋势反映了多种因素的复杂交互作用，包括药物类别特征、给药便利性、分销能力、终端使用者需求以及在治疗方案中的定位。药物类别包括生物製药、糖皮质激素和免疫抑制剂。在生物製药中，Omalizumab和Rituximab等药物备受关注；在糖皮质激素中，Methylprednisolone和泼尼松是常用药物；免疫抑制剂包括Azathioprine、胺基甲基叶酸和Mycophenolate Mofetil。这些药物类别在研发复杂性、监测要求和耐受性方面存在显着差异，这些差异会影响临床导入和医保支付方的评估。

从地理观点比较不同地区的医疗服务模式、报销环境、监管考量和创新采纳。

区域差异显着影响水痘天疱疮的临床路径、治疗途径和治疗起始曲线。在美洲，医疗保健系统将完善的专科诊所网络与先进的静脉输液技术相结合，而支付方也越来越要求签订基于真实世界证据和疗效的合同，以支持高成本治疗。这种环境有利于那些能够减少住院次数和类固醇相关併发症的治疗方法，并支持大规模的专科药房基础设施，以提供患者支持和药物依从性计画。

以研发、伙伴关係模式、供应链韧性和专业服务提供为特征的公司的策略行动和竞争定位。

水痘天疱疮领域的竞争动态受多种企业类型和策略行动的影响。创新生物製药公司专注于开发平臺，旨在拓展标靶治疗的适应症，并产生可靠的疗效比较证据。同时，学名药和生物相似药生产商则优先考虑生产扩充性、成本效益，并竞标来满足长期以来对皮质类固醇和传统免疫抑制剂的需求。

为高阶主管、医疗保健领导者、支付方和销售团队提供个人化、可操作的建议，从而加快采用速度、改善治疗效果并控製成本波动。

产业领导者应推动一系列合作行动，将临床创新转化为以患者为中心的永续医疗服务。首先，透过供应商多角化、策略性库存管理和短期生产伙伴关係，投资提升价值链韧性，可以降低关税和物流中断带来的风险。其次，建构包含随机对照试验数据和可操作的註册研究结果的可靠证据包，将有助于加强与支付方的价值对话，并争取更有利的报销条款。

概述了可靠的调查方法，包括资料来源、相关人员访谈、证据整合、检验程序和分析严谨性。

本分析所依据的研究采用了混合方法，以确保方法的严谨性和实际应用价值。主要资料收集包括对皮肤科医生、医院药剂师、专科诊所管理人员、支付方和供应链主管进行结构化访谈，以了解相关人员对诊断、治疗选择、采购和获取障碍的观点。次要资讯包括同行评审的临床文献、治疗指南、监管文件和公共声明，以验证临床和监管背景。

全面整合，为临床、商业和政策决策者提取关键见解、策略意义和前瞻性观点。

本篇综述重点关注水痘天疱疮治疗和商业领域的动态变化，其驱动因素包括临床上对减少类固醇暴露的需求、生物目标成熟的循证医学证据以及医疗保健总成本面临的系统性压力。诊断技术的进步、医疗服务模式的演变以及专业分销管道的拓展，为相关人员提供了展现实际价值和营运准备的机会。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章水痘天疱疮市场：依药物类别划分

  • 生物製药
    • Omalizumab
    • Rituximab
  • 皮质类固醇
    • Methylprednisolone
    • 强的松
  • 免疫抑制剂
    • Azathioprine
    • 胺基甲基叶酸
    • Mycophenolate Mofetil

第九章：水痘天疱疮市场：依给药途径

  • 静脉注射
  • 口服
  • 外用

第十章水痘天疱疮市场依治疗方案划分

  • 一线治疗
  • 维持治疗
  • 二级治疗

第十一章水痘天疱疮市场：依最终使用者划分

  • 居家医疗设施
  • 医院
    • 私立医院
    • 公立医院
  • 专科诊所
    • 皮肤科诊所
    • 门诊部

第十二章水痘天疱疮市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章水痘天疱疮市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章水痘天疱疮市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国水痘天疱疮市场

第十六章：中国水痘天疱疮市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AbbVie Inc.
  • Argenx SE
  • AstraZeneca plc
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline plc
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
Product Code: MRR-535C62918796

The Bullous pemphigoid Market was valued at USD 379.75 million in 2025 and is projected to grow to USD 402.44 million in 2026, with a CAGR of 6.08%, reaching USD 574.14 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 379.75 million
Estimated Year [2026] USD 402.44 million
Forecast Year [2032] USD 574.14 million
CAGR (%) 6.08%

A concise clinical and strategic overview of bullous pemphigoid outlining pathophysiology, unmet care gaps, evolving treatments, and stakeholder priorities

Bullous pemphigoid represents a prevalent autoimmune blistering condition primarily affecting older adults, characterized by subepidermal blister formation driven by autoantibodies against hemidesmosomal proteins. Clinically, the disease ranges from localized pruritic eruptions to widespread tense bullae with secondary infection risk and significant impacts on functional status and quality of life. Diagnosis typically involves clinical assessment supported by direct immunofluorescence, autoantibody testing for BP180 and BP230, and histopathology to differentiate it from other blistering disorders.

Therapeutic management has historically relied on systemic and topical corticosteroids to control inflammation and arrest blister formation, but long-term steroid exposure carries substantial morbidity in the aging patient population. Consequently, treatment approaches have evolved toward steroid-sparing strategies that prioritize immunosuppressants and, more recently, targeted biologic therapies. These shifts stem from an expanding evidence base, a greater emphasis on patient-centered outcomes, and an imperative to reduce adverse event burden for frail patients.

Across clinical and payer stakeholders, the disease presents multiple care gaps: delayed diagnosis, variability in treatment intensity, limited access to specialty dermatology services in some regions, and uneven reimbursement frameworks for high-cost therapies. These challenges create both clinical urgency and strategic opportunity for organizations that can offer safer, efficacious therapeutic options, integrated care models, and pragmatic access solutions that address the needs of older, comorbid patients.

Transformative shifts reshaping diagnosis, clinical practice patterns, and therapeutic innovation in bullous pemphigoid across care settings and specialty disciplines

Recent years have witnessed transformative shifts across diagnostic pathways, therapeutic decision making, and care delivery models for bullous pemphigoid. Advances in immunodiagnostics and broader clinician familiarity with autoantibody profiles have reduced diagnostic ambiguity, while guideline updates increasingly emphasize steroid-sparing regimens for long-term management. Concurrently, clinical evidence and real-world experience with targeted biologics have reweighted benefit-risk assessments, offering alternatives to chronic high-dose corticosteroid therapy.

Beyond clinical innovation, health-system dynamics are evolving: payers and providers are more actively judging treatments by total cost of care, adverse event avoidance, and hospitalization reduction. This orientation favors therapies that can demonstrably reduce steroid-associated complications and downstream utilization. At the same time, telemedicine and distributed care pathways have expanded follow-up capabilities for older patients, enabling earlier recognition of flares and improved adherence monitoring.

Commercially, these shifts are catalyzing new partnership models between specialty pharmacies, manufacturers, and provider networks aimed at streamlining access and patient support. Evidence generation strategies are becoming more sophisticated, combining controlled clinical trials with pragmatic studies and registries to capture outcomes relevant to regulators and payers. Taken together, these forces are repositioning bullous pemphigoid from a steroid-dominated paradigm toward a diversified therapeutic landscape that prioritizes safety, durability, and real-world effectiveness.

Anticipated cumulative effects of United States tariff changes in 2025 on supply chains, procurement, pricing pressures, and cross-border logistics

Proposed tariff adjustments in the United States for 2025 carry implications that extend into pharmaceutical supply chains, procurement practices, and pricing negotiations. Increased duties on imported active pharmaceutical ingredients, biologic components, or finished products can amplify input costs for manufacturers and contract producers, prompting reassessments of supplier portfolios. In response, organizations are likely to consider nearshoring of manufacturing, diversification of API sourcing, and longer-term supply agreements to stabilize input costs and mitigate exposure to customs delays.

These supply-side adaptations can cascade into distribution and procurement behavior. Health systems and hospital pharmacies may increase inventory buffers for critical therapies to avoid shortages, while specialty distributors could renegotiate terms to absorb volatility. For high-cost biologic therapies, where manufacturing scale and cold-chain logistics are critical, tariff-driven cost pressures may accentuate the importance of efficient downstream distribution and consolidated shipping models. Conversely, generic corticosteroids and conventional immunosuppressants, which often rely on commodity APIs, may experience increased price sensitivity in procurement tenders.

Payers and contracting teams will respond by tightening value-based purchasing criteria and reinforcing outcome-based agreements where possible. Manufacturers should therefore prioritize transparent cost modeling, supply-chain visibility, and collaborative contracting to preserve access. In addition, regulatory authorities and customs administrations will remain focal points for operational risk management, and proactive stakeholder engagement will help organizations navigate tariff-related friction while protecting continuity of care.

Segment-level strategic intelligence on therapeutic classes, administration routes, distribution channels, end-user dynamics, and therapy line implications

Segment-level dynamics in bullous pemphigoid reflect a complex interplay between drug class characteristics, administration convenience, distribution capabilities, end-user needs, and therapy line positioning. Drug class segmentation includes biologics, corticosteroids, and immunosuppressants; within biologics, therapeutic attention is centered on agents such as omalizumab and rituximab, while corticosteroids commonly involve methylprednisolone and prednisone, and the immunosuppressant category encompasses azathioprine, methotrexate, and mycophenolate mofetil. These classes differ markedly in development complexity, monitoring requirements, and tolerability profiles, which in turn influence clinical adoption and payer assessment.

Route-of-administration segmentation spans intravenous, oral, and topical modalities, with intravenous administration often linked to biologic deployment and requiring infusion infrastructure, whereas oral and topical options support broader ambulatory and home-based management. Distribution channel segmentation ranges from hospital pharmacy through online pharmacy to retail pharmacy, with online models further divided into B2B and B2C platforms that offer differentiated access and fulfillment capabilities. End-user segmentation captures homecare settings, hospitals, and specialty clinics; hospitals are further divided into private and public facilities, while specialty clinics include dermatology clinics and outpatient clinics, each with distinct referral patterns and capacity constraints.

Therapy-line segmentation defines first-line, maintenance, and second-line roles, shaping both clinical decision making and commercial positioning. First-line strategies frequently emphasize rapid disease control with manageable safety profiles, maintenance strategies prioritize durability and tolerability, and second-line interventions are reserved for refractory disease or steroid-intolerant patients. Cross-segmentally, uptake drivers include safety and efficacy evidence, route-of-administration convenience, distribution readiness, and payer reimbursement policies, with each factor exerting differential influence depending on the therapeutic and care setting involved.

Geographic perspectives that compare care delivery patterns, reimbursement landscapes, regulatory considerations, and innovation adoption across regions

Regional differences materially shape clinical pathways, access mechanisms, and adoption curves for bullous pemphigoid therapies. In the Americas, health systems combine robust specialty clinic networks with advanced infusion capacity, and payers increasingly demand real-world evidence and outcomes-based contracting to support high-cost interventions. This environment favors therapies that demonstrate reductions in hospitalizations and steroid-related complications and supports sizable specialty pharmacy infrastructure for patient support and adherence programs.

In Europe, Middle East & Africa, the regulatory landscape is heterogeneous, with European regulatory harmonization fostering centralized approvals while Middle Eastern and African markets experience variable access due to differing reimbursement frameworks and supply-chain constraints. Regional centers of dermatology excellence tend to lead clinical adoption, and public hospitals often play a key role in procurement decisions, making pricing negotiations and health-technology assessments central to access outcomes.

In Asia-Pacific, demographic trends toward aging populations increase clinical burden and demand for scalable care models. Diverse payer systems coexist with rapidly developing private sector capabilities and growing digital health adoption that supports remote monitoring and follow-up. Manufacturing capacity in some Asia-Pacific countries also presents opportunities for regional sourcing and localized supply resilience. Across all regions, cross-border logistics, regulatory alignment, and local clinical practice patterns determine the speed and extent of therapeutic uptake, and these factors should inform regional go-to-market strategies.

Corporate strategic behaviors and competitive positioning that highlight R&D focus, partnership models, supply chain resilience, and specialty service offerings

Competitive dynamics in bullous pemphigoid are shaped by several corporate archetypes and strategic behaviors. Innovative biopharmaceutical companies focus on R&D pipelines that expand indications for targeted therapies and generate robust comparative-effectiveness evidence. Generics and biosimilar manufacturers emphasize scalable production, cost-efficiency, and tender participation to address long-standing corticosteroid and conventional immunosuppressant demand.

Specialty pharmacies and integrated distribution partners are increasingly central to commercial execution, providing patient support programs, adherence monitoring, and complex logistics management that are particularly important for biologics requiring cold-chain handling. Contract development and manufacturing organizations play a pivotal role in enabling rapid scale-up and in diversifying supply across geographies to mitigate tariff and geopolitical risk. Diagnostics and laboratory service providers contribute by advancing autoantibody testing capabilities and enabling earlier, more precise diagnosis.

Strategically, leading organizations pursue collaborations that blend clinical expertise, payer-facing evidence generation, and channel optimization. Examples include co-investment in registries, outcome-based contracting pilots with payers, and partnerships with telehealth providers to enhance post-discharge monitoring. These approaches reduce time-to-adoption, address payer concerns about long-term value, and create differentiated service propositions that extend beyond product labels.

Actionable recommendations tailored for executives, medical leaders, payers, and commercial teams to accelerate adoption, improve outcomes, and manage cost dynamics

Industry leaders should pursue a set of coordinated actions to convert clinical innovation into sustainable, patient-centered access. First, investing in supply-chain resilience through supplier diversification, strategic inventory management, and near-term manufacturing partnerships will reduce exposure to tariff and logistics disruptions. Second, building robust evidence packages that combine randomized data with pragmatic registry-based outcomes will strengthen value conversations with payers and support favorable reimbursement terms.

Third, aligning commercial models with specialty pharmacy and integrated care networks will streamline patient onboarding, adherence support, and safety monitoring-particularly for biologic therapies delivered intravenously or requiring complex handling. Fourth, prioritizing patient support programs that address the unique needs of older adults, such as transportation assistance and simplified dosing regimens, will improve retention and real-world outcomes. Fifth, pursuing outcome-based contracting and risk-sharing pilots with payers can de-risk access to high-cost therapies and demonstrate commitment to measurable value.

Finally, embracing digital tools-telemedicine for follow-up, digital registries for longitudinal outcomes, and remote monitoring platforms-will enhance real-world data capture and support continuous quality improvement. Taken together, these actions provide a pathway to accelerate adoption while managing cost and preserving patient safety.

Robust research methodology overview describing data sources, stakeholder interviews, evidence synthesis, validation steps, and analytical rigor

The research underpinning this analysis used a mixed-methods approach to ensure methodological rigor and practical relevance. Primary data collection included structured interviews with dermatologists, hospital pharmacists, specialty clinic managers, payers, and supply-chain executives to capture stakeholder perspectives on diagnosis, treatment preferences, procurement, and access barriers. Secondary sources comprised peer-reviewed clinical literature, treatment guidelines, regulatory documents, and public policy statements to triangulate clinical and regulatory context.

Evidence synthesis involved iterative cross-validation of findings across sources, with thematic analysis applied to qualitative interviews to surface emerging trends and strategic priorities. Validation steps included expert review by clinical and commercial advisors and scenario testing to assess the robustness of qualitative conclusions under alternative supply-chain and reimbursement environments. The research also acknowledged limitations related to regional heterogeneity in clinical practice and the evolving evidence base for newer biologic therapies, and it therefore emphasized adaptive strategies rather than prescriptive forecasts.

Ethical considerations and data governance protocols guided primary research activities, ensuring anonymization of interview responses and adherence to applicable data-protection norms. The methodology aimed to balance depth of insight with breadth of stakeholder representation to deliver practical, defensible conclusions for decision makers.

Closing synthesis that distills critical insights, strategic implications, and future-facing considerations for clinical, commercial, and policy decision makers

This synthesis brings into focus a therapeutically and commercially dynamic landscape for bullous pemphigoid, driven by clinical imperatives to reduce steroid exposure, by the maturing evidence base for targeted biologics, and by system-level pressures on total cost of care. Diagnostic improvements, evolving care delivery models, and the proliferation of specialty distribution channels create opportunities for stakeholders that can demonstrate real-world value and operational readiness.

At the same time, external pressures such as tariff changes, supply-chain volatility, and regional regulatory diversity require proactive mitigation strategies, including supplier diversification, outcome-focused contracting, and investment in regional capabilities. Successful actors will combine scientific rigor with operational excellence, integrating clinical evidence, payer engagement, and specialty distribution to enable sustainable access.

In closing, the pathway to improved outcomes for patients with bullous pemphigoid lies in coordinated action across clinical development, commercial strategy, and supply-chain design. Organizations that adopt a holistic, evidence-driven approach will be best positioned to translate therapeutic innovation into consistent, equitable care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Bullous pemphigoid Market, by Drug Class

  • 8.1. Biologics
    • 8.1.1. Omalizumab
    • 8.1.2. Rituximab
  • 8.2. Corticosteroids
    • 8.2.1. Methylprednisolone
    • 8.2.2. Prednisone
  • 8.3. Immunosuppressants
    • 8.3.1. Azathioprine
    • 8.3.2. Methotrexate
    • 8.3.3. Mycophenolate Mofetil

9. Bullous pemphigoid Market, by Route Of Administration

  • 9.1. Intravenous
  • 9.2. Oral
  • 9.3. Topical

10. Bullous pemphigoid Market, by Therapy Line

  • 10.1. First Line
  • 10.2. Maintenance
  • 10.3. Second Line

11. Bullous pemphigoid Market, by End User

  • 11.1. Homecare Settings
  • 11.2. Hospitals
    • 11.2.1. Private Hospitals
    • 11.2.2. Public Hospitals
  • 11.3. Specialty Clinics
    • 11.3.1. Dermatology Clinics
    • 11.3.2. Outpatient Clinics

12. Bullous pemphigoid Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Bullous pemphigoid Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Bullous pemphigoid Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Bullous pemphigoid Market

16. China Bullous pemphigoid Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. AbbVie Inc.
  • 17.6. Argenx SE
  • 17.7. AstraZeneca plc
  • 17.8. Bristol-Myers Squibb Company
  • 17.9. Eli Lilly and Company
  • 17.10. F. Hoffmann-La Roche AG
  • 17.11. GlaxoSmithKline plc
  • 17.12. Novartis AG
  • 17.13. Pfizer Inc.
  • 17.14. Regeneron Pharmaceuticals, Inc.
  • 17.15. Sanofi S.A.
  • 17.16. Sun Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BULLOUS PEMPHIGOID MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BULLOUS PEMPHIGOID MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY THERAPY LINE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES BULLOUS PEMPHIGOID MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA BULLOUS PEMPHIGOID MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY OMALIZUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY OMALIZUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY OMALIZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY RITUXIMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY RITUXIMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY RITUXIMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY METHYLPREDNISOLONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY METHYLPREDNISOLONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY METHYLPREDNISOLONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY PREDNISONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY PREDNISONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY PREDNISONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY AZATHIOPRINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY AZATHIOPRINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY AZATHIOPRINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY METHOTREXATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY METHOTREXATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY METHOTREXATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY MYCOPHENOLATE MOFETIL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY MYCOPHENOLATE MOFETIL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY MYCOPHENOLATE MOFETIL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY MAINTENANCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY MAINTENANCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY MAINTENANCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY HOMECARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY HOMECARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY DERMATOLOGY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY DERMATOLOGY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY DERMATOLOGY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY OUTPATIENT CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY OUTPATIENT CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS BULLOUS PEMPHIGOID MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS BULLOUS PEMPHIGOID MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS BULLOUS PEMPHIGOID MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS BULLOUS PEMPHIGOID MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA BULLOUS PEMPHIGOID MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA BULLOUS PEMPHIGOID MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA BULLOUS PEMPHIGOID MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA BULLOUS PEMPHIGOID MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA BULLOUS PEMPHIGOID MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA BULLOUS PEMPHIGOID MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA BULLOUS PEMPHIGOID MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA BULLOUS PEMPHIGOID MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA BULLOUS PEMPHIGOID MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA BULLOUS PEMPHIGOID MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA BULLOUS PEMPHIGOID MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA BULLOUS PEMPHIGOID MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE BULLOUS PEMPHIGOID MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE BULLOUS PEMPHIGOID MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE BULLOUS PEMPHIGOID MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE BULLOUS PEMPHIGOID MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST BULLOUS PEMPHIGOID MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST BULLOUS PEMPHIGOID MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST BULLOUS PEMPHIGOID MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST BULLOUS PEMPHIGOID MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA BULLOUS PEMPHIGOID MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA BULLOUS PEMPHIGOID MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA BULLOUS PEMPHIGOID MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA BULLOUS PEMPHIGOID MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC BULLOUS PEMPHIGOID MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC BULLOUS PEMPHIGOID MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC BULLOUS PEMPHIGOID MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC BULLOUS PEMPHIGOID MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. ASEAN BULLOUS PEMPHIGOID MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. ASEAN BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 164. ASEAN BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 165. ASEAN BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 166. ASEAN BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN BULLOUS PEMPHIGOID MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN BULLOUS PEMPHIGOID MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN BULLOUS PEMPHIGOID MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 172. GCC BULLOUS PEMPHIGOID MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. GCC BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 174. GCC BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 175. GCC BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 176. GCC BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 177. GCC BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 178. GCC BULLOUS PEMPHIGOID MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 179. GCC BULLOUS PEMPHIGOID MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. GCC BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 181. GCC BULLOUS PEMPHIGOID MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPEAN UNION BULLOUS PEMPHIGOID MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPEAN UNION BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPEAN UNION BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPEAN UNION BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPEAN UNION BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPEAN UNION BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION BULLOUS PEMPHIGOID MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPEAN UNION BULLOUS PEMPHIGOID MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPEAN UNION BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION BULLOUS PEMPHIGOID MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 192. BRICS BULLOUS PEMPHIGOID MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. BRICS BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 194. BRICS BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 195. BRICS BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 196. BRICS BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 197. BRICS BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 198. BRICS BULLOUS PEMPHIGOID MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 199. BRICS BULLOUS PEMPHIGOID MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 200. BRICS BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS BULLOUS PEMPHIGOID MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 202. G7 BULLOUS PEMPHIGOID MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 203. G7 BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 204. G7 BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 205. G7 BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 206. G7 BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 207. G7 BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 208. G7 BULLOUS PEMPHIGOID MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 209. G7 BULLOUS PEMPHIGOID MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 210. G7 BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 211. G7 BULLOUS PEMPHIGOID MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 212. NATO BULLOUS PEMPHIGOID MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 213. NATO BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 214. NATO BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 215. NATO BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 216. NATO BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 217. NATO BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 218. NATO BULLOUS PEMPHIGOID MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 219. NATO BULLOUS PEMPHIGOID MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 220. NATO BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 221. NATO BULLOUS PEMPHIGOID MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 222. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. UNITED STATES BULLOUS PEMPHIGOID MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 224. UNITED STATES BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 225. UNITED STATES BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 226. UNITED STATES BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 227. UNITED STATES BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 228. UNITED STATES BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED STATES BULLOUS PEMPHIGOID MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 230. UNITED STATES BULLOUS PEMPHIGOID MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 231. UNITED STATES BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES BULLOUS PEMPHIGOID MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 233. CHINA BULLOUS PEMPHIGOID MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 234. CHINA BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 235. CHINA BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 236. CHINA BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 237. CHINA BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 238. CHINA BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 239. CHINA BULLOUS PEMPHIGOID MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 240. CHINA BULLOUS PEMPHIGOID MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 241. CHINA BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 242. CHINA BULLOUS PEMPHIGOID MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)